Roughly 1 in 10 people taking GLP-1 drugs like Zepbound, semaglutide, or tirzepatide lose less than 5% of their body weight, compared to the typical 15% to 21% weight loss. These nonresponders often spend months and thousands of dollars on medication that simply doesn't work for them, leaving them frustrated and questioning whether they're using the drug correctly. Scientists are now investigating why some bodies respond dramatically to these medications while others barely budge, pointing to genetics, hormonal differences, and other biological factors that could help doctors predict treatment success from the start. What Makes Some People Nonresponders to Weight-Loss Drugs? Jessica Layeux, a 42-year-old cybersecurity expert from Minnesota, took Zepbound for 15 months and lost only a pound or two. She wasn't alone in her experience. While clinical trials show that GLP-1 drugs work remarkably well for most people, they reveal a consistent pattern: roughly 10% of participants are nonresponders who see minimal results. The question that researchers are racing to answer is why. The leading theory involves genetics. Marie Spreckley, a researcher at the University of Cambridge, explains that genetic variations influence hunger levels, fullness signals, and metabolism,how efficiently the body burns energy. Since semaglutide and tirzepatide work primarily by reducing appetite and quieting what patients call "food noise," people whose obesity stems from factors unrelated to food intake may see less benefit. "When we think about the whole alphabet soup of hormones that control our weight, it's almost embarrassing to think that we can fix obesity by just addressing two," said Dr. Beverly Tchang, an obesity medicine doctor at Weill Cornell Medicine. The two hormones targeted by these drugs primarily regulate appetite and blood sugar, but weight is controlled by a much more complex system. Other biological factors also play a role. Estrogen, for example, interacts with GLP-1 pathways in the gut and brain, potentially making the body more sensitive to the drugs' appetite-dampening effects. This may explain why men appear more likely to be nonresponders than women, and why hormone replacement therapy might improve weight-loss results among postmenopausal women. Additionally, the longer someone has lived with obesity, the less likely GLP-1 medications may work well. People with type 2 diabetes tend to have a harder time losing weight on these drugs than those without diabetes, and other inflammatory conditions could also reduce how well someone responds. How to Determine If You're a Nonresponder and Find Alternatives? - Wait for a Clear Response Window: Dr. Amy Sheer, an obesity medicine doctor at University of Florida Health, typically waits four to six months before concluding that a patient won't respond to a GLP-1 drug, giving the medication adequate time to work at therapeutic doses. - Consider Genetic Testing: Some doctors are now using genetic tests that analyze genes involved in appetite, satiation, and metabolism to predict which weight-loss drug might work best for an individual patient, though these tests haven't yet been proven to improve outcomes in independent clinical trials. - Explore Combination Therapy: When Layeux's genetic test suggested she needed to eat more calories to stay full and didn't maintain fullness for long, her doctor recommended adding phentermine alongside Zepbound, resulting in 20 pounds of weight loss within a month. - Switch to Alternative Medications: Researchers found that nonresponders to GLP-1 drugs lost significant weight on phentermine-topiramate, a different medication that acts on different brain pathways that suppress appetite. - Discuss Bariatric Surgery: For some patients, bariatric surgery remains an option, though it's typically considered after other treatments have been attempted. Dr. Andres Acosta, an obesity medicine physician at the Mayo Clinic and senior author of a recent genetic study, noted that doctors would ideally use patients' characteristics to determine which weight-loss drug they should try first. His research analyzed genetic profiles between people who lost weight on older GLP-1 drugs and those who didn't respond well, finding that nonresponders often succeeded with phentermine-topiramate instead. The emotional toll of being a nonresponder shouldn't be underestimated. Layeux described the experience as "extremely defeating," especially when surrounded by media coverage celebrating these drugs as "miracle" treatments. "No matter what I do, these 'miracle drugs' don't work," she said, reflecting the self-blame many nonresponders experience. What Happens When Patients Stop Taking These Drugs? For those who do respond to GLP-1 drugs, a separate concern emerges: what happens when they stop taking the medication? A large real-world study from Cleveland Clinic involving nearly 8,000 patients provides reassuring news that differs significantly from earlier clinical trials. Clinical trials suggested that stopping semaglutide would result in regaining roughly two-thirds of lost weight within a year. However, the Cleveland Clinic analysis found something different. Among nearly 8,000 patients who discontinued injectable semaglutide or tirzepatide, average weight one year later had barely shifted. Those treated for obesity regained a mean of just 0.5% of body weight. Those treated for type 2 diabetes actually lost an additional 1.3% on average. The key difference between trial results and real-world outcomes comes down to what patients do next. Most patients who stopped their medication didn't simply abandon treatment altogether. Within a year of stopping, 19.6% of patients had restarted the same medication. Another 35.2% pursued some form of alternative treatment. Combined, that means more than half the cohort was doing something deliberate about their weight within twelve months of their initial prescription lapsing. "Many patients do not give up on their obesity treatment journey, even if they need to stop their initial medication," said Hamlet Gasoyan, a researcher with Cleveland Clinic's Center for Value-Based Care Research, who led the study. The breakdown of alternative treatments reveals the variety of paths patients took. About 27% switched to a different medication, including older obesity drugs or crossed between semaglutide and tirzepatide. Twenty percent restarted their original prescription. Another 14% attended structured lifestyle modification visits with dietitians, exercise specialists, or other health professionals. Less than 1% moved forward with bariatric surgery within the first year, though that figure rose to 1.3% at two years. Insurance coverage significantly shaped who could restart treatment and how quickly. Patients using the drugs for type 2 diabetes restarted their original medication at nearly double the rate of those using them for obesity, 23.5% versus 14.2%. Coverage for these drugs is considerably broader when diabetes is the documented indication. For obesity alone, insurance authorization remains inconsistent and frequently denied, pushing some patients toward self-pay options or abandonment of treatment altogether. While average weight change after discontinuation was small in both groups, individual outcomes varied considerably. Among patients who had started treatment for obesity, 55% gained weight during the year after stopping. Forty-five percent either held steady or continued losing. Among those who had used the drugs for diabetes, the pattern was more favorable: 56% kept losing or stayed the same, while 44% gained. Dr. Beverly Tchang offers hope for those struggling to find the right medication: "While the right medication might not exist for them right now, that doesn't mean we're not going to have it in six months, one year or two years." Pharmaceutical companies are already developing new drugs that target additional hormones beyond the two currently addressed by semaglutide and tirzepatide.
